• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Aquatech Acquires Koch's Direct Lithium Extraction Business, Integrating Li-Pro™ DLE into the PEARL™ Technology Platform

    9/16/25 5:21:00 PM ET
    $A
    $EQNR
    $SLI
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Integrated oil Companies
    Energy
    Get the next $A alert in real time by email

    CANONSBURG, Pa., Sept. 16, 2025 /PRNewswire/ -- Aquatech has acquired Koch Technology Solutions' (KTS) direct lithium extraction (DLE) business, integrating the Li-Pro™ Lithium Selective Sorption (LSS) technology and extensive Li-Pro IP portfolio into the PEARL™ process technology platform.

    Aquatech and Koch logos

    The acquisition of KTS' Li-Pro LSS technology adds direct lithium extraction to Aquatech's extensive process flowsheet IP, lithium conversion and crystallization capabilities. With this addition, Aquatech's PEARL platform becomes the only commercially proven, end-to-end flowsheet solution for lithium processing. Spanning lithium extraction, purification and refining, the PEARL process technology platform delivers high-purity battery materials for electric vehicles (EV) and utility-scale electricity storage systems (ESS).

    The integration and optimization of upstream and downstream lithium processing will empower lithium resource owners with modularized process solutions at scale. This approach improves project bankability by removing process risk, accelerating project schedules and reducing the total cost of lithium production. Li-Pro LSS will be available under technology license as part of the PEARL full flowsheet licensing offerings.

    As part of the acquisition, all ongoing lithium extraction projects utilizing Li-Pro technology and associated licenses, agreements and performance guarantees will be transferred to Aquatech. This includes KTS' role in the Joint Development Agreement (JDA) with Standard Lithium Ltd. (TSXV:SLI) (NYSE:A) in the Smackover Formation, where they have completed over 12,000 operational cycles using Li-Pro technology at their demonstration plant and achieved an average lithium recovery of over 95%. It also includes a licensing agreement with Smackover Lithium, a joint venture between Standard Lithium and Equinor (NYSE:EQNR) (OSE:EQNR), for the first phase of its South West Arkansas project. The project is among the largest lithium projects in the US, with an initial phase of 22,500 tons per annum (tpa) of lithium carbonate equivalent targeting first production in 2028, with significant scope for future expansion.

    "Koch Technology Solutions has proven the Li-Pro LSS technology as a successful DLE solution, and the time has come to scale it for the market. Aquatech is uniquely placed to scale this technology and deliver it into projects as a cost competitive, end-to-end process solution, creating significant value for the lithium industry," commented Dave Dotson, President at Koch Engineered Solutions, the parent company of KTS.

    "We are confident that our legacy lithium customers will benefit from the broader offering of Aquatech. More broadly, Koch continues to maintain an active interest in the success of the technology via its investments in several key companies within the lithium minerals and lithium battery industries," said Garrett Krall, Critical Minerals & Lithium Business Leader at Koch Technology Solutions. 

     "Fragmented technology offerings increase project cost, risk and time-to-market, which has hindered the ramp-up of urgently needed critical minerals production in the Americas and Europe. Bringing Li-Pro into the PEARL technology platform solves this pressing industry need by offering the only proven full flowsheet solution that encompasses both upstream and downstream lithium processing technology," commented Venkee Sharma, Executive Chairman at Aquatech.

    Mr. Sharma continued, "We welcome the KTS Li-Pro team to Aquatech and commend them on the pioneering work done to develop Li-Pro LSS. With over 45 years of experience scaling commercially proven technologies, we are excited to evolve Li-Pro LSS both as a standalone technology offering and as part of the PEARL platform."

    About Aquatech

    Aquatech leverages innovative technology, engineering and execution leadership to solve the world's most demanding process challenges in lithium, critical minerals and industrial water. Aquatech's technology portfolio, project execution and service capabilities are grounded in a culture of performance excellence built up over four decades, with thousands of facilities using our solutions in over 60 countries.

    www.aquatech.com

    About Koch Technology Solutions

    Koch Technology Solutions (KTS) is a leader in technology licensing, delivering operating efficiency and capital productivity for licensees deploying the technologies in our portfolio. KTS partners with companies developing chemical process technologies to create attractive licensing solutions for commercial deployment, helping to bring the next generation of process technologies to the market.

    www.kochtechsolutions.com

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/aquatech-acquires-kochs-direct-lithium-extraction-business-integrating-li-pro-dle-into-the-pearl-technology-platform-302558347.html

    SOURCE Aquatech

    Get the next $A alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $A
    $EQNR
    $SLI

    CompanyDatePrice TargetRatingAnalyst
    Agilent Technologies Inc.
    $A
    5/28/2026$145.00Neutral → Buy
    BofA Securities
    Agilent Technologies Inc.
    $A
    5/27/2026$153.00Outperform
    RBC Capital Mkts
    Equinor ASA
    $EQNR
    5/7/2026$38.00 → $40.00Hold
    TD Cowen
    Standard Lithium Ltd.
    $SLI
    4/29/2026$4.75Outperform
    Evercore ISI
    Equinor ASA
    $EQNR
    3/24/2026$40.40Underweight → Equal-Weight
    Morgan Stanley
    Equinor ASA
    $EQNR
    3/20/2026Sell → Neutral
    UBS
    Equinor ASA
    $EQNR
    2/5/2026$22.00 → $25.00Hold
    TD Cowen
    Equinor ASA
    $EQNR
    2/5/2026Buy → Neutral
    BofA Securities
    More analyst ratings

    $A
    $EQNR
    $SLI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Agilent, OpenAI, BCG Collaborate to Accelerate Customer-Focused, AI-Driven Scientific Innovation

    Agilent Technologies Inc. (NYSE:A) today announced a collaboration with OpenAI and Boston Consulting Group (BCG) to accelerate the deployment of artificial intelligence (AI) across the company's products, operations, and customer workflows. "AI is a top priority, and this partnership reflects both our ambition and our execution commitment — to build the enduring capability, operating model, and capacity required to consistently deliver AI‑driven innovation value for our customers," said Padraig McDonnell, president and CEO of Agilent. "Through this collaboration with OpenAI and BCG, we are accelerating deployment of AI across our business while advancing more intelligent instruments, soft

    6/3/26 7:00:00 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Agilent Receives FDA Approval for Expanded Use of PD-L1 IHC 22C3 pharmDx on Dako Omnis in Esophageal Squamous Cell Carcinoma, Triple-Negative Breast Cancer, Cervical Cancer, and Gastric or Gastroesophageal Junction Adenocarcinoma

    Approval expands PD-L1 testing onto an automated workflow to support treatment decisions with KEYTRUDA® (pembrolizumab)¹,² Agilent Technologies Inc. (NYSE:A) today announced that the U.S. Food and Drug Administration (FDA) has approved the expanded use of PD-L1 IHC 22C3 pharmDx, Code GE006, for use on the Dako Omnis platform to aid in identifying patients in the United States with esophageal squamous cell carcinoma (ESCC)3, triple-negative breast cancer (TNBC)4, cervical cancer5, and gastric or gastroesophageal junction (GEJ) adenocarcinoma6, who may be eligible for treatment with KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy. This approval expands access to PD-L1 testing across

    6/2/26 4:15:00 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Recommendation from the nomination committee of Equinor ASA

    The nomination committee of Equinor ASA ((OSE:EQNR, NYSE:EQNR) recommends that the company's corporate assembly elects Jarle Roth as new chair of the board of directors of Equinor ASA. Furthermore, the nomination committee recommends re-election of Anne Drinkwater as deputy chair, in addition to Finn Bjørn Ruyter, Haakon Bruun-Hanssen, Mikael Karlsson, Fernanda Lopes Larsen and Dawn Summers as members of the board of directors of Equinor ASA. Jon Erik Reinhardsen, who has been the chair of the board since 2017, would like to resign from the board of directors. Jarle Roth has been a member of the board since1 December 2025. Jarle Roth is an independent advisor. Roth has held CEO roles in m

    6/1/26 2:02:00 AM ET
    $EQNR
    Integrated oil Companies
    Energy

    $A
    $EQNR
    $SLI
    Leadership Updates

    Live Leadership Updates

    View All

    Agilent Names Michael Buckner as Chief Legal Officer

    Agilent Technologies Inc. (NYSE:A) today announced the appointment of Michael Buckner as chief legal officer, effective today. Buckner brings nearly three decades of experience as a senior global legal executive, with a proven track record of building and leading high-performing teams and deep expertise in complex transactions and regulatory environments. "We are thrilled to welcome Michael to the Agilent team," said Padraig McDonnell, Agilent president and CEO. "His experience leading global legal organizations, combined with his expertise across governance, compliance and regulatory matters, will play a key role as we continue to advance our strategy and deliver for our customers and

    5/4/26 8:00:00 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Agilent Showcases Cancer Research Solutions at AACR 2026

    Agilent Technologies Inc. (NYSE:A) will present new technologies, scientific collaborations, and integrated workflows supporting cancer research and diagnostics at the American Association for Cancer Research (AACR) Annual Meeting on April 17–22, 2026, in San Diego, California. At the meeting, Agilent will highlight advances designed to connect discovery research, translational science, and companion diagnostics development, reflecting the growing demand for more integrated approaches across the cancer research continuum. Among the technologies featured is the BioTek Cytation 9 cell imaging multimode reader, the newest addition to the Cytation series of cell imaging and multimode micropla

    4/15/26 8:00:00 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Oklo Announces Changes to its Board of Directors and Management Team to Support its Continued Growth

    Oklo welcomes Dr. Mark Peters, David Christian, Derek Kan, and David Park as new directors, bringing decades of experience executing complex and highly technical projects across a range of industries Oklo appoints Michael Thompson as Lead Independent Director Oklo announces plan to transition Pat Schweiger from Chief Technology Officer to a senior technical advisor Oklo Inc. (NYSE:OKLO), an advanced nuclear technology company, today announced changes to its Board of Directors and management team designed to enable Oklo to meet its ambitious deployment goals across its integrated power-fuel-isotopes business. "Over the past two years, we have built distinct business units respons

    4/14/26 4:15:00 PM ET
    $GL
    $OKLO
    $SLI
    Life Insurance
    Finance
    Electric Utilities: Central
    Utilities

    $A
    $EQNR
    $SLI
    SEC Filings

    View All

    SEC Form 6-K filed by Equinor ASA

    6-K - EQUINOR ASA (0001140625) (Filer)

    6/2/26 6:05:06 AM ET
    $EQNR
    Integrated oil Companies
    Energy

    SEC Form 10-Q filed by Agilent Technologies Inc.

    10-Q - AGILENT TECHNOLOGIES, INC. (0001090872) (Filer)

    6/1/26 4:09:02 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form 6-K filed by Equinor ASA

    6-K - EQUINOR ASA (0001140625) (Filer)

    6/1/26 6:05:06 AM ET
    $EQNR
    Integrated oil Companies
    Energy

    $A
    $EQNR
    $SLI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Agilent upgraded by BofA Securities with a new price target

    BofA Securities upgraded Agilent from Neutral to Buy and set a new price target of $145.00

    5/28/26 8:43:55 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    RBC Capital Mkts initiated coverage on Agilent with a new price target

    RBC Capital Mkts initiated coverage of Agilent with a rating of Outperform and set a new price target of $153.00

    5/27/26 9:00:20 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    TD Cowen reiterated coverage on Equinor with a new price target

    TD Cowen reiterated coverage of Equinor with a rating of Hold and set a new price target of $40.00 from $38.00 previously

    5/7/26 6:47:50 AM ET
    $EQNR
    Integrated oil Companies
    Energy

    $A
    $EQNR
    $SLI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Gonsalves Rodney (Amendment)

    4/A - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)

    10/20/23 1:07:25 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Gonsalves Rodney bought $288 worth of shares (3 units at $111.09), increasing direct ownership by 0.01% to 24,222 units (SEC Form 4)

    4 - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)

    9/29/23 4:03:46 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $A
    $EQNR
    $SLI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Dolsten Mikael sold $216,672 worth of shares (1,600 units at $135.42), decreasing direct ownership by 22% to 5,548 units (SEC Form 4)

    4 - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)

    6/2/26 4:01:41 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Senior Vice President Buckner Michael Steven was granted 8,872 shares, increasing direct ownership by 59,147% to 8,887 units (SEC Form 4)

    4 - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)

    5/21/26 4:06:22 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Senior Vice President May Simon covered exercise/tax liability with 368 shares, decreasing direct ownership by 3% to 14,015 units (SEC Form 4)

    4 - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)

    5/12/26 4:11:55 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $A
    $EQNR
    $SLI
    Financials

    Live finance-specific insights

    View All

    Agilent Reports Second-Quarter Fiscal Year 2026 Financial Results

    Delivers strong Q2 results and raises FY26 revenue growth, margin expansion, and non-GAAP EPS(4) guidance on continued operational momentum Second-quarter fiscal year 2026 Revenue of $1.83 billion for the second quarter ended April 30, 2026, representing growth of 10.0% reported and up 6.3% core(1) compared with the second quarter of 2025. GAAP operating margin of 21.7%; non-GAAP operating margin(2) of 26.4% expanded by 130 basis points year-over-year and 180 basis points sequentially. GAAP net income of $339 million; earnings per share (EPS) of $1.20, an increase of 60% from the second quarter of 2025. Non-GAAP net income(3) of $423 million; non-GAAP EPS(3) of $1.49, an incre

    5/27/26 4:05:00 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Equinor ASA: Announcement of cash dividend of 3.6041 NOK per share for fourth quarter 2025

    Equinor ASA ((OSE: EQNR, NYSE:EQNR) announced on 4 February 2026 a cash dividend per share of USD 0.39 for fourth quarter 2025. The NOK cash dividend per share is based on average USDNOK fixing rate from Norges Bank in the period plus/minus three business days from record date 15 May 2026, in total seven business days. Average Norges Bank fixing rate for this period was 9.2414. Total cash dividend for fourth quarter 2025 is consequently NOK 3.6041 per share. On 27 May 2026, the cash dividend will be paid to relevant shareholders on Oslo Børs (Oslo Stock Exchange) and to holders of American Depositary Receipts ("ADRs") on New York Stock Exchange. This information is published in accordanc

    5/21/26 1:50:00 AM ET
    $EQNR
    Integrated oil Companies
    Energy

    Agilent Announces Cash Dividend of 25.5 Cents per Share

    Agilent Technologies Inc. (NYSE:A) today announced a quarterly dividend of 25.5 cents per share of common stock. The quarterly dividend will be paid on July 22, 2026, to all shareholders of record as of the close of business on June 30, 2026. The timing and amounts of future dividends are subject to the determination and approval of Agilent's board of directors. About Agilent Technologies Agilent Technologies, Inc. (NYSE:A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent's full range of solutions includes instruments, software, services, and expertise that provide tru

    5/20/26 4:27:00 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $A
    $EQNR
    $SLI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Agilent Technologies Inc.

    SC 13G/A - AGILENT TECHNOLOGIES, INC. (0001090872) (Subject)

    11/12/24 1:27:37 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SC 13G filed by Agilent Technologies Inc.

    SC 13G - AGILENT TECHNOLOGIES, INC. (0001090872) (Subject)

    11/12/24 11:54:03 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SC 13G filed by Agilent Technologies Inc.

    SC 13G - AGILENT TECHNOLOGIES, INC. (0001090872) (Subject)

    11/4/24 10:57:57 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials